GSK Plc is a long-term underperformer among Europe’s Big Pharma stocks. And with key drug patents set to expire and vaccine ...

International biotechnology company GlaxoSmithKline is moving its vaccine and infectious disease research teams to Cambridge, ...

The PMCPA has turned party pooper, coming down on GSK after learning that a U.K. employee celebrated a post about a ...

GSK PLC closed 21.63% short of its 52-week high of £18.24, which the company reached on May 16th.

Bernstein analyst Florent Cespedes maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £22.90.

The United Kingdom-based pharma giant, GlaxoSmithKline Pharmaceuticals or GSK's Indian arm GSK Pharmaceuticals, saw its ...

Shares of GlaxoSmithKline Pharmaceuticals Ltd ended at ₹2,608, up by ₹275.75, or 11.82%, on the BSE. Brokerage firms, ...

Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has bee ...

Thousands of U.S. health agency employees were terminated and told it was for poor performance, though they'd received strong ...

GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...

Shares of GSK PLC GSK rose 1.79% to £14.47 Thursday, on what proved to be an all-around rough trading session for the stock ...

GlaxoSmithKline share price has surged more than 36% in two sessions after the announcement of Q3 results. The stock has ...